Pain
-
We have examined the interactions between NMDA receptors and opioid effects in isolated neonatal rat spinal cord. Electrical stimulation of a lumbar dorsal root evoked a nociceptive-related slow ventral root potential (sVRP) recorded at the corresponding ipsilateral ventral root. The kappa opiate receptor agonist U69,593 (2.5 nM-1 microM) depressed sVRP area by a maximum of 80%, EC50 was approximately 33 nM. ⋯ MK-801 co-applied with morphine blocked the rebound increase in sVRP area following naloxone. These results suggest that (1) both mu and kappa receptor agonists exert similar selective depressant effects on spinal nociceptive neurotransmission; (2) mu but not kappa agonists exert prolonged excitatory effects that oppose the depression; and (3) NMDA receptors play a role in determining opioid analgesic potency and naloxone-precipitated hyperresponsiveness. The results may be related to initial steps in the development of acute tolerance to mu opioids, and suggest that tolerance to kappa opioids may have a different mechanism.
-
A chronic allodynia-like response to mechanical stimulation was observed in rats after severe spinal cord ischemia. This allodynia-like response was not relieved by most conventional analgesics used for treating chronic neuropathic pain. The present experiments evaluated the effects of systemically administered excitatory amino acid receptor antagonists, including the non-competitive N-methyl-D-aspartate (NMDA) receptor/channel blockers MK-801 and dextromethorphan, the competitive NMDA receptor antagonist CGS 19755 and a competitive antagonist of the alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid (AMPA) receptor NBQX, on the chronic allodynia-like response in spinally injured rats. ⋯ It is concluded that systemic NMDA, but not AMPA, receptor antagonists may have an analgesic effect upon the chronic allodynia-like response. However, the analgesic effect of all NMDA antagonists was associated with side effects. Dextromethorphan, which is clinically tolerated and produced less side effects, may be useful for treating chronic pain associated with central nervous system injury.
-
The present study describes a new test of tonic pain to be used as an animal model of persistent pain. First, pain responses and edema produced by subcutaneous injection of increasing doses of honey bee venom into the hind paw of the rat were quantified. Second, the effect of morphine and aspirin on the pain responses was investigated. ⋯ Analgesia was produced by morphine and aspirin, indicating that the bee venom test can be used to test analgesic drugs. Concurrent administration of bee venom and formalin produced pain responses similar to formalin alone, with a less profound interphase depression and a longer duration. The data suggest that the bee venom test is a valid animal model of experimental tonic pain.
-
In this study, Freund's adjuvant-induced monoarthritis in the rat hind paw was used to induce chronic pain and inflammation. In order to compare the basal outflow, electrically-evoked release and total content of calcitonin gene-related peptide like immunoreactivity (CGRP-LI) with previously reported changes in substance P (SP-LI), the lumbar enlargement of monoarthitic (complete Freund's adjuvant-treated, CFA rat) and control (incomplete Freund's adjuvant-treated, IFA rat) spinal cords were used. During the 4-wk period after injection, neither the basal nor the evoked release of CGRP-LI from CFA cords differed from controls. ⋯ However, the release of both peptides was significantly increased to the same extent in IFA and normal tissue but to a lesser extent in CFA cords, by superfusion with the opioid antagonist naloxone (1 microM). In conclusion, CGRP-LI, unlike SP-LI, did not appear to be susceptible to any changes in the lumbar enlargement of the rat spinal cord during inflammation of the hind paw. In addition, CGRP-LI release was increased by antagonism of opiate but not GABAB receptors, suggesting that during chronic inflammation of one hind paw, the GABAB ergic system, unlike the opioid system, might be activated to selectively inhibit the enhanced SP-LI release but not CGRP-LI release which is not changed.
-
'Diffuse noxious inhibitory controls' or DNIC is the inhibition of multireceptive neurons in the dorsal horn of the spinal cord that results when a noxious stimulus is applied to a region of the body remote from the neuron's excitatory receptive field. Although this phenomenon is well-documented, the behavioral consequences of DNIC are not clear. The present study was undertaken to determine how nocifensor withdrawal reflexes evoked by a noxious stimulus are altered by application of a second noxious stimulus to a distant part of the body. ⋯ When the forepaw or hindpaw was placed in water exceeding 49 degrees C the tail flick reflex to acute noxious radiant heat was inhibited. In contrast, noxious conditioning stimuli, regardless of temperature or location, had no effect on the latency for hindpaw withdrawal evoked by an acute noxious stimulus, but did produce a change in reflex topography from flexion to extension. These results, along with previous research on DNIC, suggest that intense noxious stimuli: (1) inhibit the tail flick reflex via inhibition of multireceptive neurons in the dorsal horn; (2) disinhibit hindpaw extensor motoneurons by inhibiting the activity of multireceptive neurons involved in hindlimb flexion; and (3) reduce pain sensation by inhibiting multireceptive neurons projecting to the brain (see Model in Discussion).